The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non‐carriers with mild cognitive impairment due to Alzheimer's disease is a research paper published in Alzheimer s & Dementia Translational Research & Clinical Interventions (2024). On theSindex it has a DataRank of 0. It has been cited 7 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Science Foundation
Grant: R01AG061091
National Science Foundation
Grant: R56AG055416
National Science Foundation
Grant: R01AG048349
NIA NIH HHS
Grant: P30 AG066507
National Institutes of Health
Grant: 5R01AG061091-02
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
National Institutes of Health
Grant: 1R56AG055416-01
A Phase 3 pivotal trial of AGB101 to slow progression in MCI due to Alzheimer's Disease
National Institutes of Health
Grant: 5R01AG048349-04
PHASE II/III trial for Slowing Progression in Mild Cognitive Impairment
FWCI
2.02
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals